Adjuvant Capital
Venture capitalNew York · Series A–Late Stage · 19 people tracked
Investment thesis
Adjuvant targets high-burden public health challenges through venture capital investment in life science technologies, particularly in infectious disease, maternal and child health, nutrition, and reproductive health. The firm recognizes substantial opportunity in underserved markets where healthcare spending in emerging economies is growing rapidly, yet venture capital allocation remains low. By financing technologies with demonstrated human safety and efficacy, Adjuvant aims to accelerate global availability of impactful medical innovations while generating differentiated returns alongside meaningful health outcomes.
Source: firm website, verified Jul 21, 2026.
Team · 19 people
from the firm's websiteWhat they invest in
from 3 of 19 portfolio companiesBiotech ×2Healthtech ×2Medical Devices ×2AI & Machine Learning ×1FemTech ×1Wellness & Fitness ×1
HQs:Nigeria×1
Investments · 19 tracked
founders shown can be your intro path54Gene conducts genomics research and provides related services to increase the representation of African genetic data in medical research, which aims to advance healthcare solutions globally.
HealthtechWellness & FitnessLagos, NG
Gatumi Aliyu(Founder)inAbasi Ene-Obong(Founder)inOgochukwu Francis Osifo(Founder)in
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry. The company targets an unmet clinical need where no approved therapeutic options currently exist.
BiotechFemTechHealthtechMedical Devices
ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.
AI & Machine LearningBiotechMedical Devices
Frequently asked questions
- What stage does Adjuvant Capital invest at?
- Adjuvant Capital invests at the Series A, Series B, Late Stage stages.
- What sectors does Adjuvant Capital focus on?
- Adjuvant Capital focuses on Biotech, Digital Health, Healthtech, Impact & Social Good, Medical Devices.
- Where is Adjuvant Capital located?
- Adjuvant Capital is headquartered in New York, US.
Similar investors
Novo Holdings is a holding and investment company managing the assets of the Novo Nordisk Foundation, one of the world's largest enterprise foundations. The firm invests in life science companies across all development stages and manages a diversified portfolio including equities, bonds, real estate, infrastructure, and private equity.
B Capital is a venture capital firm managing $12+ billion in assets under management with 200+ early to late-stage portfolio companies across 9 global locations. The firm operates dedicated stage-based funds supporting entrepreneurs throughout the company-building lifecycle.
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.